Buzz Stocks: The Coca-Cola Co, LogMeIn Inc, and Recro Pharma Inc

U.S. stocks are up after a series of earnings reports, including wins for blue chips Apple Inc. (NASDAQ:AAPL) and Boeing Co (NYSE:BA). Among equities in focus today are fellow Dow component The Coca-Cola Co (NYSE:KO), cloud service stock LogMeIn Inc (NASDAQ:LOGM), and biotech Recro Pharma Inc (NASDAQ:REPH).

• KO is down 3.5% at $43.34, following a mixed earnings report. The Coca-Cola Co beat analysts' expectations for per-share earnings, but missed on quarterly sales and cut its full-year organic revenue growth forecast, citing international headwinds. The blue-chip stock is now struggling to stay in the black on a year-to-date basis, and could end beneath its 10-month moving average for the first time since September. In the option pits, put buying was especially popular leading up to earnings, with KO's 10-day put/call volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) of 2.73 sitting in the 96th percentile of its annual range.

• LOGM is up 20.2% at $83.82 -- and just off an all-time high of $86.40 -- after news that the cloud services provider will be merging with Citrix Systems, Inc.'s (NASDAQ:CTXS) GoTo unit, in an all-stock deal. Option bulls have been keen on LOGM, with its 50-day ISE/CBOE/PHLX call/put volume ratio of 1.19 sitting in the top one-third of its annual range. LogMeIn Inc shares received a series of price-target hikes today, ranging from $78 (Cowen and Company) to $100 (Piper Jaffray).

• REPH is up 31.4% at $10.09 -- and rallied as high as $12.50 earlier -- after releasing positive late-stage trial data for its non-opioid intravenous painkiller, Meloxicam. This bull gap has pushed REPH to year-to-date highs, and above resistance at its 200-day moving average. REPH is now up 12.2% since the beginning of 2016. Some short sellers may be kicking rocks today, because even though REPH's short interest is down 6.2% over the last two reporting periods, shorted shares still represent two week's worth of pent-up buying demand, at Recro Pharma Inc's average daily volume.

Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check